NZ521037A - Gene disruption methodologies for drug target discovery - Google Patents

Gene disruption methodologies for drug target discovery

Info

Publication number
NZ521037A
NZ521037A NZ521037A NZ52103701A NZ521037A NZ 521037 A NZ521037 A NZ 521037A NZ 521037 A NZ521037 A NZ 521037A NZ 52103701 A NZ52103701 A NZ 52103701A NZ 521037 A NZ521037 A NZ 521037A
Authority
NZ
New Zealand
Prior art keywords
gene
cells
diploid
allele
genes
Prior art date
Application number
NZ521037A
Other languages
English (en)
Inventor
Terry Roemer
Bo Jiang
Charles Boone
Howard Bussey
Original Assignee
Elitra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elitra Pharmaceuticals Inc filed Critical Elitra Pharmaceuticals Inc
Publication of NZ521037A publication Critical patent/NZ521037A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ521037A 2000-02-18 2001-02-20 Gene disruption methodologies for drug target discovery NZ521037A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18353400P 2000-02-18 2000-02-18
PCT/US2001/005551 WO2001060975A2 (en) 2000-02-18 2001-02-20 Gene disruption methodologies in fungi for drug target discovery

Publications (1)

Publication Number Publication Date
NZ521037A true NZ521037A (en) 2004-09-24

Family

ID=22673211

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ521037A NZ521037A (en) 2000-02-18 2001-02-20 Gene disruption methodologies for drug target discovery

Country Status (7)

Country Link
EP (1) EP1292668A2 (ko)
JP (1) JP2003523197A (ko)
KR (1) KR20020097180A (ko)
AU (1) AU2001243204A1 (ko)
CA (1) CA2398861A1 (ko)
NZ (1) NZ521037A (ko)
WO (1) WO2001060975A2 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20030082591A1 (en) * 2001-07-24 2003-05-01 Donald Awrey Methods for gene disruption and uses thereof
US7465568B2 (en) 2002-04-26 2008-12-16 Bristol-Myers Squibb Company Essential fungal polynucleotides, polypeptides, and methods of use
GB0228704D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
GB0228697D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
GB0228702D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel therapeutic target
GB0228694D0 (en) * 2002-12-09 2003-01-15 Oxford Glycosciences Uk Ltd Novel threapeutic target
EP1466974A1 (en) * 2003-04-11 2004-10-13 Max-Delbrück-Centrum Für Molekulare Medizin Inducible site-directed mutagenesis through conditional gene rescue
CN108707554B (zh) * 2018-05-21 2021-06-29 河北省农林科学院植物保护研究所 一对玉蜀黍黑粉菌组合及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824545A (en) * 1995-11-01 1998-10-20 Millennium Pharaceuticals, Inc. Identification of eukaryotic growth-related genes and promoter isolation vector and method of use
CA2218446A1 (en) * 1997-12-12 1999-06-12 Mcgill University New candida albicans kre9 and uses thereof
EP1161544A1 (en) * 1999-03-11 2001-12-12 GPC Biotech Inc. Generation of conditional yeast mutants, methods and reagents related thereto

Also Published As

Publication number Publication date
AU2001243204A1 (en) 2001-08-27
WO2001060975A2 (en) 2001-08-23
CA2398861A1 (en) 2001-08-23
EP1292668A2 (en) 2003-03-19
JP2003523197A (ja) 2003-08-05
KR20020097180A (ko) 2002-12-31
WO2001060975A3 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
US20030180953A1 (en) Gene disruption methodologies for drug target discovery
US20030119013A1 (en) Identification of essential genes of Aspergillus fumigatus and methods of use
Clark et al. Yeast pheromone response pathway: characterization of a suppressor that restores mating to receptorless mutants
WO2004067709A2 (en) Identification of essential genes of aspergillus fumigatus and methods of use
US20040014955A1 (en) Identification of essential genes of cryptococcus neoformans and methods of use
US6221597B1 (en) Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
NZ521037A (en) Gene disruption methodologies for drug target discovery
US6200803B1 (en) Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US20050079619A1 (en) Gene disruption methodologies for drug target discovery
US20050019931A1 (en) Nucleic acids encoding antifungal drug targets and methods of use
US5723436A (en) Calcineurin interacting protein compositions and methods
Hsueh et al. A homolog of Ste6, the a-factor transporter in Saccharomyces cerevisiae, is required for mating but not for monokaryotic fruiting in Cryptococcus neoformans
Klosterman et al. Ubc2, an ortholog of the yeast Ste50p adaptor, possesses a basidiomycete-specific carboxy terminal extension essential for pathogenicity independent of pheromone response
AU2002231144A1 (en) Gene disruption methodologies for drug target discovery
EP1173619B1 (en) Identification of candida albicans essential fungal specific genes and use thereof in antifungal drug discovery
US6197517B1 (en) Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
AU2002254729A1 (en) Identification of essential genes of aspegillus fumigatus and methods of use
CA2366069A1 (en) Generation of conditional yeast mutants, methods and reagents related thereto
US20020103154A1 (en) Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferation drugs
US20040106173A1 (en) Bot1: target for antifungal agents
Gibbons Phenotypic switching in candida albicans-a candidate gene approach

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: MERCK AND CO., INC., US

Free format text: OLD OWNER(S): ELITRA PHARMACEUTICALS, INC.

PSEA Patent sealed